← SCP Cost Explorer Read on SCP Wiki ↗
SCP-6470 Thaumiel ~ medium confidence
SCP-6470
Expected annual
$49.7B
One-time setup
$73.2B
Annual recurring
$47.5B
Personnel
244000
Corrected Foundation operational one-time budget ≈ $73.2B (main drivers: production capacity/equipment, communications-access infrastructure, compensation reserve, last-mile assets); recurring Foundation operational cost ≈ $47.55B/year (main drivers: staff wages, logistics, pharmacovigilance, disability support subsidies). Systemic (non-Foundation) economic impact is tracked separately and estimated at one-time ≈ $150B and recurring ≈ $200B/year. This differs materially from the original report primarily by moving macroeconomic/economic-impact reserves out of Foundation operational spend and explicitly zeroing concealment/cover-up costs because the program is public and globally visible.
🏗️ One-Time Capital Costs Total: $73.2B
Comm Access Infrastructure $20.0B
Global upgrades to captioning, visual/tactile alert systems, and subsidized public-access real-time transcription: itemized examples include scaling real-time captioning platforms and servers (~$6B), national public-alert upgrades and signage (~$4B), subsidized national high-availability captioning contracts and AI model licensing (~$5B), deployment of public-venue display/alert hardware globally (~$3B), and training/initial operations (~$2B) = $20B. Itemized to comply with Rule 1 for large one-time investments.
Compensation Reserve One Time $20.0B
Initial capitalization of a Foundation-administered compensation and long-term care reserve for demonstrable harms attributable to administration: reserve sized for initial capitalization to cover large, low-probability claims and early long-term care obligations. Reserve components: litigation buffer ~$5B, initial long-term care seed ~$10B, emergency payouts ~$5B = $20B.
Contingency Reserve $9.5B
Program contingency = 15% of the subtotal of above one-time Foundation items. Calculated and itemized rather than arbitrarily declared; used as escalation buffer for cost overruns and re-runs.
Assistive Device Procurement $7.0B
Bulk procurement/subsidies for inexpensive AAC devices and low-cost smartphones/data vouchers for low-income populations. Example: target 100M subsidized devices at average delivered cost $70/device = $7.0B. Itemized because >$1B.
Facilities $5.0B
Breakdown: build/retrofit ~40 GMP fill-finish plants to reach throughput (40 plants × ~$100M plant shell and services = $4,000,000,000) + centralized utilities, site commissioning, containment upgrades and spare capacity ~$1,000,000,000 = $5,000,000,000. Itemized because >$1B per Rule 1.
Last Mile Assets $3.0B
Purchase/lease of mobile clinics, regional cold/ambient trucks, charter capacity, drones/boats/helicopters for remote access. Example build-up: 10,000 vehicles/units averaged ~$200k/unit including outfitting = $2.0B + mobile clinic modules and rapid-deploy field units ~$1.0B = $3.0B. Itemized components provided because >$1B.
Intelligence And Diplomacy Setup $2.5B
Up-front diplomatic liaison teams, covert liaison budgets (to coordinate with sovereign states/GoIs), and contingency operational planning and standing task forces. Breakdown: diplomatic/liaison initial payments ~$800M, task force deployment prep ~$700M, covert contingency funds ~$1.0B = $2.5B.
Equipment $1.2B
Capital equipment for production and automation: ~100 high-speed fill-finish lines and robotics (~$600M), high-throughput chromatography and bulk synthesis apparatus (~$300M), plant-scale sterile isolators/cleanroom equipment and validation rigs (~$300M) = $1.2B.
Monitoring Setup $1.0B
Assay development and distribution for a biomarker/saliva test, national registry back-end build, and initial kit manufacturing capacity (lab kit manufacture tooling, software platform build).
Training Education Setup $1.0B
Curriculum development, trainer networks and initial global rollout of sign-language/non-verbal communication training infrastructure.
It Infrastructure One Time $1.0B
Global immunization/administration registry development, supply-chain tracking platform initial deployment, and cybersecurity baseline hardening.
Initial Research And Lab Setup $600.0M
Analytical/QC lab buildout and specialized instrumentation for high-throughput batch release testing (mass spectrometers, sterility suites, endotoxin testers, lab automation) and initial validation.
Regulatory And Legal One Time $500.0M
One-time multinational emergency-authorisation coordination, legal teams, negotiation of indemnities and governmental memoranda of understanding required to enable a global roll-out.
Continuity Governance One Time $500.0M
One-time support to update emergency/governance communications, procure non-verbal court/meeting equipment and train senior governance staff in non-verbal continuity procedures.
Antidote Rnd One Time $200.0M
Initial R&D funding to investigate reversal/antidote pathways, early toxicology and small-molecule screens, and initial small-batch manufacture for contingency stocks.
Procurement Setup $150.0M
Establish global procurement and contracting offices, supplier qualification programs, and initial bulk-purchase agreements.
Cold Chain Storage $0
Analyst assumptions and accompanying documentation indicate the product is room-temperature stable; a cold-chain capital program is not required. If stability data change, this line must be revisited.
Cover Programs One Time $0
Zeroed per Rule 3: the program is explicitly public (Foundation cooperating with governments and public Code materials exist). Large-scale concealment/cover-up is neither feasible nor necessary; Foundation does not fund a global secrecy/cover program for SCP-6470.
🔄 Annual Recurring Costs Total: $47.5B/yr
Staff Wages $14.2B/yr
Annual fully-burdened payroll for Foundation-paid operational staff. Derived from a headcount model: vaccinators/administration 150,000 @ $50k FBC/year = $7.5B; administrative coordination 10,000 @ $60k = $0.6B; medical officers 5,000 @ $120k = $0.6B; manufacturing/operators 12,000 @ $80k = $0.96B; security (Foundation-funded contract staff complement) 30,000 @ $70k = $2.1B; logistics operators 20,000 @ $60k = $1.2B; R&D/QC staff 5,000 @ $120k = $0.6B; IT staff 2,000 @ $120k = $0.24B; monitoring/contact centers 10,000 @ $40k = $0.4B = $14.2B total. Headcount breakdown is in the personnel section.
Logistics And Transport $10.0B/yr
Annualized global freight and last-mile logistics: bulk ocean freight to hubs, airlift charters to remote regions, last-mile ground/droned deliveries, fuel and contracted operators. Breakdown: international freight/logistics contracts ~$3.0B, airlift/charter surge capacity ~$2.5B, last-mile operations and contractors ~$4.5B = $10.0B.
Pharmacovigilance $5.0B/yr
Sustained post-administration surveillance, emergency response readiness, hospital surge funding assistance and a rolling fund for urgent medical responses. Breakdown: surveillance systems and staffing ~$1.0B, hospital surge funding and rapid-response deployments ~$2.5B, emergency treatment stockpiles and logistics ~$1.5B.
Disability Supports $5.0B/yr
Targeted Foundation-funded disability and social-support subsidies for populations demonstrably disadvantaged by loss of vocalization (supplementing national programs). This line is a Foundation operational subsidy, not the full societal welfare cost (major long-term social services remain systemic). Breakdown: targeted cash subsidies ~$2.0B, interpreter/service vouchers and mental-health programs ~$2.0B, employment retraining grants ~$1.0B.
Security Services $1.5B/yr
Contracted security for production sites, hubs and escorted shipments. Itemized: private security contracts and convoys ~$1.0B, air/port protection and surge protection support ~$0.5B.
Waste Management $1.5B/yr
Medical waste handling and large-scale disposal/recycling programs for single-use containers and packaging generated during distribution. Breakdown: collection/logistics ~$700M, processing/incineration/recycling contracts ~$800M.
Research And Monitoring $1.2B/yr
Ongoing analytical capacity, batch release testing, pharmacovigilance analytics teams and cohort follow-ups. Includes lab operating budgets, sample throughput costs and study operations.
Facilities Maintenance $1.2B/yr
Operating costs for production plants, field-deployable assets and mobile clinics (utilities, maintenance contracts, lease costs). Breakdown: plant utilities/maintenance ~$700M/yr, last-mile asset maintenance ~$300M/yr, facility security & permits ~$200M/yr.
Supplies And Consumables $1.2B/yr
Primary packaging, single-dose containers, droppers, tamper-evident seals, labels, per-dose QC disposables and sterile consumables. Representative breakdown: packaging materials ~$600M/yr, QC disposables/reagents ~$300M/yr, other sterile consumables ~$300M/yr.
Intelligence And Diplomacy Ops $1.0B/yr
Ongoing diplomatic liaison teams, intelligence monitoring and negotiation budgets to keep non-cooperative jurisdictions engaged and to counter organized resistance.
Public Communications $1.0B/yr
Multilingual public information campaigns, misinformation response teams and outreach to maximize uptake and compliance.
Comm Access Maintenance $1.0B/yr
Operational costs for scaled captioning services, platform licensing, ongoing visual/tactile alert maintenance and contracted human captioners for high-risk venues.
Compensation Payouts $1.0B/yr
Recurring annual payouts from claims not covered by the initial reserve and administrative costs for claims processing. Large adverse events would drive additional scenario-specific payouts.
Raw Materials And Bulk Active $800.0M/yr
Bulk active ingredient(s), excipients and pharmaceutical-grade reagents purchased at scale for production campaigns. Example per-dose blended cost assumed ~$0.10/dose × 8B = $800M for a single-production-year campaign; actual campaign purchase timing may concentrate costs in production months.
Training And Ppe $600.0M/yr
Refresher training, PPE replenishment, short competency checks and infection-control consumables for administration workforce worldwide.
Assistive Device Services $500.0M/yr
Subsidized data plans, device repair networks and service contracts for distributed assistive devices and low-cost smartphones.
Training Education Ops $300.0M/yr
Ongoing training operations, refresher courses and trainer salaries for sign-language and non-verbal communications education.
It Infrastructure Ops $300.0M/yr
Hosting, cybersecurity operations, data governance and platform ops for registries and tracking systems.
Antidote Stockpile Ops $100.0M/yr
Ongoing manufacturing and readiness costs for any reversal agents developed (small stockpile maintenance, cold/storage if required).
Continuity Governance Ops $100.0M/yr
Ongoing support for non-verbal continuity of governance training and equipment refreshes.
Cover Story And Legal $0/yr
Zeroed per Rule 3: concealment is not feasible nor required given the public, coordinated global rollout; routine multinational regulatory/legal budgets are captured elsewhere (regulatory/ legal one-time and other recurring legal activity captured under intelligence/diplomacy and compensation/legal payouts).
⚡ Cost Scenarios
📊 Baseline (baseline) $47.5B/yr
90.0% probability / year
Orderly global rollout and steady-state operations with cooperative governments, no large safety signals; Foundation spends recurring operational budget to manage production, distribution, monitoring and adaptation subsidies.
high governmental cooperation no major unexpected safety signals logistics proceed as planned
🚨 Minor Incident $52.5B/yr
7.0% probability / year +$5.0B vs baseline
Localized clusters of severe adverse events or targeted logistical failures requiring a measurable surge in healthcare response, temporary production pauses and targeted legal/compensation payouts.
regional safety signal triggering mass hospital visits localized supply-chain disruptions requiring airlift surges legal claim clusters
🚨 Major Breach $107.5B/yr
3.0% probability / year +$60.0B vs baseline
Widespread adverse events, significant political resistance, or large-scale litigation and care obligations requiring major international deployments, large compensation payouts and sustained long-term social-support funding from the Foundation.
widespread adverse reaction signal multiple governments withdraw cooperation prompting forced access operations large-scale litigation and long-term care obligations
👥 Personnel 244000 total
Role Count Notes
Vaccinator / Field Administrator 150000 Mass administration workforce (Foundation-funded tranche). Per-person fully-burdened annual cost used: $50,000; majority of global vaccinators may be provided/co-funded by national partners but Foundation funds a large central cohort to guarantee coverage in underserved areas.
Administrative Staff / Coordination 10000 Regional and global coordination staff for procurement, records, and local operations; fully-burdened annual cost ~$60,000.
Medical Officers / Clinical Oversight 5000 Clinical leadership, triage, adverse-event management; fully-burdened annual cost ~$120,000.
Manufacturing / Plant Operators 12000 Operators, QC technicians and maintenance staff across production plants; fully-burdened annual cost ~$80,000.
Security Personnel (Foundation-funded complement) 30000 Contracted/embedded security staff and protected convoy personnel funded by the Foundation in higher-risk zones; cost reflected in security_services and staff_wages lines.
Logistics / Transport Operators 20000 Drivers, drone operators, aircrew and logistics coordinators supporting distribution and last-mile operations.
R&D and QC Scientists 5000 Analytical chemists, pharmacologists and clinical-research staff maintaining quality control and ongoing studies.
IT / Data / Registry Staff 2000 Engineers, sysadmins and data-governance staff operating immunization registries and tracking platforms.
Contact Center / Monitoring Staff 10000 Adverse-event monitoring, hotlines and case-management staff for pharmacovigilance activities.
📋 Confidence Notes
Re-evaluation materially reallocated several large items compared to the original report: (1) All economy-wide macroeconomic losses and an 'economic impact reserve' were moved out of Foundation operational budgets into the systemic_economic_impact bucket per Rule 4; (2) concealment/cover-up one-time and recurring costs were zeroed because the rollout is public/cooperative and concealment infeasible (Rule 3); (3) large (> $1B) Foundation line items were broken into explicit subcomponents in notes to comply with Rule 1. Remaining uncertainties: per-dose material cost and chemical stability (which would materially change cold-chain and packaging costs), true adverse-event incidence (which drives pharmacovigilance/compensation needs), and the degree of co-funding by nation-states vs Foundation (which would reduce Foundation line items).
← SCP-6469 ↑ All SCPs SCP-6471 →